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Summary In previous studies, highly heterogeneous uptake of '3'1-labelled chimeric monoclonal antibody G250 (['3'11]cG250) in prmary renal
cell carcinomas has been observed (intratumoral differences > factor 100). In this study, we investigated a possible correlation between
intratumoral antibody uptake and four immunohistochemicalty determined parameters: G250 antigen expression, blood vessel density,
neovascularization and percentage of viable tumour cells. Whole tumour slices of four different tumours were cut into 1-cm3 cubes, and in
each cube the ['31ljcG250 uptake was determined. The correlation between ['31lcG250 uptake and each individual parameter was determined
in a multiple regression analysis. Additionalty, the data were reanalysed after introducing arbitrary cut-off values for each parameter. If a
sample showed expression of a parameter above the introduced threshold value, this sample fuffilled one condition. Subsequentty, the
Pearson correlation coefficients were calculated from ['31lcG250 uptake and the number of fulfilled conditions (0-3). All tumour samples with
high ['31lJcG250 uptake [> 0.l1% of the injected dose per gram (ID g-1)] showed high antigen expression (> 50%). However, not all samples
with high antigen expression displayed high uptake. A statisticalty significant correlation between ['3'l1cG250 uptake and antigen expression
was found (3 = 0.44, 0.69 and 0.74) in three out of four tumours analysed. Of the other determined parameters, no consistent correlation with
[131lJcG250 uptake was found; only the percentage of viable tumour cells correlated significantty in two out offour tumours (p = 0.80 and 0.26).
Calculation of the Pearson correlation coefficients showed a statistically significant correlation between ['31l1cG250 uptake and an increased
number of fulfilled conditions in all tumours, indicating that each of the individual parameters contribute to the uptake of [1311]cG250. These
observations indicate that high antigen expression is a prerequisite for high antibody uptake. However, regional differences in antibody uptake
within a tumour cannot be explained by antigen expression alone.
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Radioimmunoscintigraphv and radioimmunotherapy w-ith radio-
labelled monoclonal antibodies (MIAbs) are relativelv nexx
approaches in the diagnosis and management of cancer. Although
recent studies have shown that radioimmunotherapy in haemato-
logical malignancies can lead to complete and lasting responses in
the majority of patients (Juweid et al. 1995: Press et al. 1995:
Kaminski et al. 1996) more modest results hax-e been reported for
solid tumours (Wilder et al. 1996. review). Marked heterogeneitx
of intratumoral antibody uptake has frequently been obserned and
is thought to be an important factorlimiting the therapeutic efficacy
of radioimmunotherapy. It has been postulated that heterogeneic
antibody uptake mi,ght be explained by heterogeneity in expression
of the tumour-associated antigen (Wilder et al. 1996) and/or by
xascular parameters such as xascular volume. blood flow- rate or
xascular permeabilitx (Blumenthal et al. 1992). Insight into the
factors that determine antibody uptake may lead to approaches to
achiex e optimal. more homogeneous antibodv uptake.
In a phase I protein dose escalation studx- wxith "II-labelled
chimeric MAb G250 (cG250) in patients with primary renal cell
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carcinoma (RCC). excellent tumour targeting >-as observed and
dosimetric analy'sis indicated that therapeutic responses minght be
achieved ifhigh doses of radioactivitx w-ere administered (Steffens
et al. 1997). Howexer. marked heterogeneitv in tumour uptake was
obserxed: uptake ofMAbcG250 in tumour samples ranged betseen
0.0015% and 0.1651% of the injected dose per gram (%cIDg-)
wxithin the same tumour. Here x-e present the results of a study
investigating whether this heterogeneity could be attributed to a
series of parameters that could be determined immunohistochemi-
cally: tumour-associated antigen G250 expression. blood x-essel
density. neovascularization or percentage ofxiable tumour cells.
MATERIALS AND METHODS
Tumour specimens and monoclonal antibodies
Four primarn tumours ofpatients who under%xent a radical tumour
nephrectomv wxere studied. All patients participated in the phase I
cG250 protein dose escalation study and had been injected w-ith
[''I]cG250 1 week before surger-. Tumours wxere numbered in
order of study entrance of the respectixve patients: the amount of
injected MAb cG250 is listed in Table 1. Followxing resection of
the primarv tumour. whole tumour slices (1 cm thick) were cut
into cubes of 1 cm. Each cube xxas numbered and cut in half. One
half was used to determine the [''I]cG250 uptake in the sample
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Table 1 Tumour data
Tumour Doses of MAb Tumour No. of samples Min 1311 uptake Max 1311 uptake Mean '3'1 uptake
no. cG250 (mg) weight (g) analysed (% ID g-1) (% ID g-1) (% ID g-') ± s.d.
1 10 840 40 0.0015 0.1651 0.0187 ± 0.0323
2 50 1200 31 0.0013 0.0063 0.0028 ± 0.0011
3 50 520 36 0.0025 0.0099 0.0056 ± 0.0017
4 5 730 33 0.0013 0.5233 0.0380 ± 0.0885
aWeight of complete tumour nephrectomy specimen (including perirenal fat and remaining normal kidney tissue).
(7 dass p.i.) using a gamma counter (1480 Wizard 3. Wallac Ov.
Turku. Finland). the other half was snap frozen and used for
immunohistochemical analysis as described below. Uptake in
tumour samples was expressed as %ID g- tumour tissue.
Immunohistochemistry
Four different parameters were investigated: expression of the
tumour-associated antigen G250 (MAb G250.) blood vessel
densitx (MAb PAL-E). neovascularization (MAb CD31) and
percentage of viable malignant ceHs [MAb RCK-102 combined
with haematoxvlin and eosin (H&E)].
The ceneration. characteristics and reactivits of MAb G250
(Centocor Europe. Leiden. The Netherlands). MAb PAL-E
(Monosan. Uden. The Netherlands). MAb CD-31 (Pharnincgen.
San Diegyo. CA. USA) and MAb RCK-10' (a kind gift from
Professor Dr Ramaekers. Department of Pathology. UniversitN
Hospital Nijmegen. The Netherlands) have been described previ-
ously (Schlingremann et al. 1985: Oosterwijk et al. 1986:
Ramaekers et al. 1990: DeLisser et al. 1993). In brief. G250 is a
murine MAb reactix-e w-ith the antigen G250. expressed in all
clear-cell RCCs and the majorits ofnon-clear cell RCCs. PAL-E is
a murine MAb reactixe with tissue ofendothelial origin. CD-31 is
a murine MAb reactive with the platelet endothelial cell adhesion
molecule 1(PECAM-1). which is expressed durinc angiogenesis.
RCK 102 is a murine MAb directed against human cvtokeratin 5
and 8 expressed in virtuallx all human epithelial cells.
Crvostat sections (4 gm) A-ere acetone fixed. washed. incubated
for 1 h at room temperature with 100gl of 10 jgc ml-' MAb G250.
MAb PAL-E. MAb CD31 or MAb RCK-102. Subsequently
sections were washed and reacted with 1:160 phosphate-buffered
saline (PBS) diluted peroxidase-labelled rabbit anti-mouse Ir
(Rampo. Dako. Carpentine. CA. USA). After another A-ash
sections were developed w-ith 3-3'-diaminobenzidine/0.03%
hydrogen peroxide. For each staining a known antioen G'50-
postive section (positive control) w-as included. In addition. for
each staining the complete procedure was carried out omitting the
incubation step Wxith the reactive antibody (negatixe control).
Scoring of stained sections
Stained slides of tumour samples were scored at 100 x magnifica-
tion using a 10 x 10 ocular counting grid. Each section was scored
entirely: every field of view was scored as < 5%. 5-25%. 25-50%.
50-75% and 75-100% cells positixe and a wxeighed mean w-as
calculated. Oxerall. the mean number offields ofXiewx per section
Aas 60. In samples Aith residual normal kidney tissue the
percentage of RCK-102-positive cells wxas corrected for the pres-
ence ofnon-malignant epithelial cells.
Table 2 Cut-off values for fulfilment of a condition for the different
parameters
Parameter Cut-off value
0o G250antigen positve > 25%
% RCK-102 positive > 50%o
Sum of 00 PAL-E positive and O CD-31 positive > 100o/o
Reconstruction of [I31IJcG250 uptake
For each tumour slice a computerized reconstruction of
[ILII]cG250 uptake was made using a Siemens Icon system
(Siemens. Hoffman Estates. IL. USA). Uptake in the 1 cmr tumour
samples (%ID g- ) was mapped on to a 64 x 64 matrix. thus recre-
ating, an image of the tumour slice. After interpolation betw-een
adjacent matrix elements the uptake was displayed using a linear
colour scale. Reconstructed pictures ,A-ere compared % ith the
radioimmunoscintigrams obtained before surger.
Autoradiography
Foreach tumour. macro autoradiography Aas performed on anumber
of selected sections (2-4 samples per tumour). Briefly. high-perfor-
mance autoradiography films (Hvperfilm. Amersham. Sweden) %vere
superimposed on unstained sections. Films were exposed in auto-
radiography cassettes equipped x-ith enhancer screens and developed
after several exposure periods ( 1.2 and 3 Aeeks).
Statistical analysis
In the first instance. the ["lI]cG250 uptake %vas analysed using
multiple regression per patient by the four parameters: G250
antigen expression. blood vessel densitv. neovascularization and
percentage viable malignant cells. In addition. the tmo parameters
concernin *vascularitswere combined to obtain ageneral measure
for vascularitv. and multiple regression w-as performed on three
parameters. Concerning multiple regression analysis. the standard-
ized regression coefficients (beta values for z-scores of indepen-
dent variables) are displayed.
Additionally. the data were reanaly-sed after introducing, arbi-
trar- cut-off values for each parameter as indicated in Table 2. If a
sample showed expression of a parameter aboxe the introduced
threshold value (e.g. antiaen G250 expression > 50%). this sample
fulfilled one condition. Ifa sample showed expression oftmo para-
meters above the introduced threshold xalue [e.g. antigen G250
expression > 50% and combined vascularity (PAL-E and CD-31)
> 100%] this sample fulfilled two conditions. etc. It was hvpothe-
sized that hiah [ 'I]cG250 uptake is only possible if a certain
British Joumal ofCancer (1998) 78(9), 1208-1213 0 Cancer Research Campaign 19981210 MG Steffens etal
Figure 1 Computerized reconstruction of ['31IJcG250 uptake in tumour slice
no. 1. Note the resemblance between the reconsrsucted image of the ex vivo
mneasured uptake in the slice and the immrunoscintigram
number of conditions is fulfilled. i.e. sufficient antigen G250
expression. enough viable malignant cells and good vascularity.
whereas if one or more of these conditions were not fulfilled
[I''I]cG250 uptake remained lower. For each sample. the number
of fulfilled conditions (0-3) was counted according to the cut-off
points (Table 2). For each tumour. the Pearson correlation coeffi-
cient was calculated to explain the ["'I]cG250 uptake (after log
transformation) from the number offulfilled conditions.
RESULTS
Distribution of [131OcG25O
Analysis of the uptake of ['"'I]cG250 in the tumour samples
revealed a highly heterogeneous distribution ofthe antibody in two
ofthe four tumour slices analysed. In some cases measured differ-
ences in uptake of [''I]cG250 in the tumour samples exceeded a
factor 100 (tumour 1). Both patients with tumours showing a
heterogeneous ['"I]cG250 distribution received a relatively low
amount of MAb cG250 (5 and 10 mg). whereas the other two
patients received a high amount of MAb cG250 (50 mg). As has
been observed with murine G250 (Oosterwijk et al. 1993). tumour
saturation may occur at higher protein dose levels (2 25 mg).
Saturation of G250 epitopes on tumour cells leads to a more
homogeneous distribution but inevitably also to a lower uptake in
terms of % ID g-' (Steffens et al. 1997). An overview ofthe ranges
in cG250 tumour uptake in all tumours is shown in Table 1. As
illustrated by the reconstructed image of one of the tumor slices.
Figure 2 Whole-b radioimmunoscintgram (postenor view). Arrows,
primary tumour (no. 1) of the left kidney. In the upper pole an area with high
[131lcG250 uptake is visible, whereas te mid- and lower pole show much
less ['I" ]cG250 uptake
certain hot areas with high uptake were embedded in regions
with much lower uptake (Figure 1). In all four cases reconstructed
images always closely resembled the preoperative radioimmuno-
scintigramns: an example is shown in Figure 2.
Autoradiography
The autoradiograms of selected tumour samples showed a hetero-
geneous distribution of ['I`]cG250 within a tumour sample. An
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Figure 3 A H&E staining of a secton of a tumour sample (T) with adjacent normal kidney tissue (NK). B Immunohistochemical staining (serial section) for
antigen G250 expression. C Autoradiogram of the whole secton superimposed over the H&E-stained secton. Note the sharp delineation between tumour and
normal kidney tissue. Also note the heterogeneous distributon of[131])cG250 within the sample despite the clear homogeneous antigen expression (B)
example ofsuch an autoradiograph. superimposed over the original
H&E-stained section. is shown in Figure 3C. Certain areas within
the section do not show [l`'I]cG250 uptake on the autoradiogram.
However. these 'cold areas' showed the same amount of antigen
expression as adjacent areas with high uptake (Figure 3B).
Immunohistochemistry
Antigen G250 was expressed in all of the analysed tumour slices.
Immunohistochemical analysis revealed that all tumour samples
with high uptake (>0.% ID- g) also showed high antigen expres-
sion (> 50%). However, the reverse was not true: not all samples
with high antigen expression showed high ["`I]cG250 uptake.
In all tumour slices examined MAb PAL-E showed a more
heterogeneous staining pattern than MAb CD-31. In general the
percentage ofCD-31-positive cells in a sample was higher than the
percentage ofPAL-E-positive cells. indicating active angiogenesis
in the tumours. RCK-102 staining clearly distinguished viable
epithelial tissue from (reactive) stromal tissue or necrotic tissue.
Statistical analysis
In three out offour tumours analvsed (nos 1. 3 and4) a statisticalls
significant correlation between [I 1I]cG250 uptake and antigen
expression was found (J = 0.44. 0.69 and 0.74 respectively).
whereas in the other tumour such a correlation was not found
( = -0.22). In two tumours (nos 2 and 4) [1`'I]cG250 uptake
correlated significantly with the percentage of tumour cells in the
samples (1 = 0.80 and 0.26). Thus. multiple regression per patient
did not lead to a uniform conclusion about the influence of the
parameters (Table 3). possibly because of collinearity of the inde-
pendent variables.
Analysis of the number of fulfilled conditions leads to more
uniform results: all analysed tumours showed a statistically signif-
icant relationship between the number of fulfilled conditions and
[I' lI]cG250 uptake (Table 4).
DISCUSSION
The mechanism governing antibody uptake and especially factors
influencing antibody uptake in solid tumours is largely unknown.
However. insight into these factors is important. as heterogeneous
antibody uptake may hlmit the efficacy of radioimmunotherapy of
sohd tumours.
In the present study the correlation between heterogeneity in
tumour uptake of MAb ['"I]cG250 in primary RCC tumours and
four immunohistochemically determined parameters - antigen
expression. vessel density. neovascularization and percentage of
viable. malignant cells - was investigated.
The results of this study indicate that high antigen expression is
an important factor for effective tumour targeting. However. the
mechanism governing antibody uptake cannot be explained by
antigen expression alone: multiple regression analysis showed a
statistically significant correlation between [' I]cG250 uptake and
antigen G250 expression in three out of four tumours. Although
statistically significant. this correlation was not always very strona
(tumour no 1. 0 = 0.44). which suaaests that other factors might
also play a role.
Although introduction of 'cut-off-values' for the parameters that
were investiaated is arbitrar. there seems to be a clear
relationship between the number of fulfilled conditions and
['3I]cG250 uptake. indicating that when certain conditions are
present in a tumour sample - antigen G250 expression. vascularity
andpercentage viable tumourcells above acertain threshold -higher
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Table 3 Influence of the parameters on ['l']-cG250 uptake per patient expressed as standardized regression coefficients (beta) and corresponding
significance level
Tumour n cG250 RCK-102 PAL-E CD-31 Vasculrity
no. expression expression expression expression (PAL-E + CD-31)
(3 P (3 P (3 P (3 P (3 P
1 40 0.44 0.36 4 0.01 4 -0.27 4 -0.26 4
2 31 -0.22 " 0.80 -0.22 -0.22 -0.39
3 36 0.74 0.07 4 -0.11 4 0.31 t 0.19 4
4 33 0.69 0.26 0.10 4 -0.19 t 0.01 4
n. number of tumour samples. P= significance level: tP> 0.10, t0O05 < P< 0.10, '0.01 <P< 0.05. P< 0.01.
Table 4 Pearson correlatin coefficients (r) between median (p50) ['31 -cG250 uptake and the number of fuffilled conditions
No. offulfilled LMedian V'rJcG250
Tumour no n condtihons uptae (p50) r P-value
13 0 0.0041
1 5 1 0.0058 0.39 0.01
13 2 0.0086
9 3 0.0136
8 0 0.0022
2 11 1 0.0028 0.35 0.05
11 2 0.0036
1 3
0 0
3 5 1 0.0041 0.47 0.004
7 2 0.0044
24 3 0.0060
1 0
4 9 1 0.0013 0.72 0.001
12 2 0.0078
11 3 0.0378
n. number of tumour samples.
["'I]cG250 uptake occurs. This obser'ation confirms that antibody
uptake results from a combination of factors rather than from one
factor alone.
There is compelling esvidence from animal studies that high
antigen expression of the recognized tumour-associated antigen is
important for high antibody uptake: Shockley et al ( 1992) investi-
gated accumulation of three anti-melanoma antibodies (MAbs
436. INDI and 9.2.27) in two different human melanoma
xenografts in nude mice and concluded that antibody accumulation
was primanrly determined by antigen expression levels. although
other physiological parameters. e.g. vascular permeability and
vascular volume. could not be excluded. One of the few studies
elegantly showing that enhanced antigen expression can result in
enhanced antibody uptake was performed by Greiner et al (1987):
these investigators were able to show that up-regulation of the
tumour-associated antigen TAG72 by human interferon alpha
(IFN-ax) treatment was accompanied by an increase in MAb B72.3
uptake. They concluded that IFN-a treatment might be a modality
to overcome antigenic heterogeneity and enhance the effect of
monoclonal antibody therapy. Similarly. Wilder et al (1993) found
that increased antigen expression induced by hyperthermia sas
associated with augmented MAb NR-LU-10 uptake in s.c. HCT-8
human colonic adenocarcinoma xenografts in nude mice.
Detailed investigations in patients in which factors determining
antibody uptake are studied are rare. and the few results ofclinical
studies are contradictory: Buist et al (1995) investigated the rela-
tion between a number oftumour characteristics and uptake of the
MAbs OV-TL 3 and chimeric MOv18 in tumour samples of
patients with ovarian carcinoma. A close correlation between anti-
body uptake and antigen expression was shown. whereas no rela-
tion was found with tumour size. histological classification or
percentage ofcancercells. Murray et al ( 1995) studied the effect of
enhanced TAG-72 antigen expression following LFN-a treatment
in relation to tumour uptake of MAb CC 49 in metastatic breast
cancer patients. Although IFN-a treatment significantly up-regu-
lated TAG-72 expression. there was no significant increase in anti-
body uptake. suggesting that other factors limited antibody uptake
in this setting.
Jain et al (1990) have postulated a number of physiological
barriers that mitht contribute to poor tumour localization of anti-
bodies: heterooenous blood supply. (locally) elevated interstitial
fluid pressure and large transport distances in the interstitium.
Based on a mathematical model it has been postulated that bindingy
of the antibody to antigen might reduce the diffusion rate of the
antibody. i.e. the hypothesized 'binding barrier' (Fujimori et al.
1990). Because of macro- and microscopic tumour heterogeneitv
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the influence of the factors mentioned above may vary from one
location to another in the same tumour and from one time point to
the next (Jain, 1990). In an earlier clinical study with murine MAb
G250 (mG250) no apparent relation was found between the intra-
tumoral distribution of ['131ImG250, injected 8 days before
surgery, and the distribution of [99-TcJhuman serum albumin
(reflecting tumourperfusion), injected a few hours before surgery
(Oosterwijk et al, 1993).
Morphologically, RCCs have a well established vascular bed.
which is supposedly more leaky to macromolecules than the
vasculature of normal tissue. This does not imply that all ntmour
regions are well perfused. Assuming that antibody uptake is facili-
tated by active perfusion and a concentration gradient, a well-
established vascular bed alone is not sufficient for appropriate,
homogeneous antibody targeting oftumours. Boucher et al (1996)
described that increased interstitial fluid pressure was a direct
result of the angiogenesis within a tumour. Thus, when enhanced
interstitial fluid pressure limits antibody uptake, it seems likely
that areas with abundant neovascularization would be poorly
accessible to antibody. However, in the present study no correla-
tion was found between ['311]cG250 uptake and CD-31 expression
or PAL-E expression. Nevertheless, this study showed in all
tumours that acertain amount ofvascularization (afulfilled condi-
tion) correlates significantly with [1311]cG250 uptake when other
necessary conditions (e.g. certain antigen expression) are also
fulfilled. Apparently enhanced interstitial fluid pressure in tumour
tissue seems to play a less important role in MAb uptake than
might be expected.
In conclusion, the present study indicated that high G250
antigen expression is aprerequisite, andprobably the main driving
force, for high cG250 antibody uptake. However, the fulfilment of
other conditions, e.g. a certain amount of vascularization, also
seems necessary for the establishment ofhigh antibody uptake.
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